Anis Ansari, MD
Nephrology · Clinton, IANPI 1487602553
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 72 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 25 manufacturers, the largest accounting for just 11.7% — the pattern of someone who eats at a lot of different presentations.
Across 72 payments — averaging $16.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$138
- Otsuka America Pharmaceutical, Inc.$116
- AstraZeneca$108
- Bayer$106
- Amgen$81
- Johnson & Johnson$73
- plus $565 from 19 others
What the payments were for
- Food & beverage$1,189100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 8 | $138 |
| Otsuka America Pharmaceutical, Inc. | 8 | $116 |
| AstraZeneca(2 entities) | 7 | $108 |
| Bayer | 6 | $106 |
| Amgen | 5 | $81 |
| Johnson & Johnson | 4 | $73 |
| Lilly USA, LLC | 4 | $70 |
| Novartis | 3 | $52 |
| Mylan Specialty L.p. | 3 | $49 |
| Daiichi Sankyo Inc. | 2 | $42 |
| Mallinckrodt Hospital Products Inc. | 2 | $41 |
| Teva Pharmaceuticals USA, Inc. | 2 | $36 |
| OPKO Pharmaceuticals, LLC | 2 | $34 |
| Boehringer Ingelheim | 2 | $32 |
| Ardelyx, Inc. | 2 | $29 |
| Sunovion Pharmaceuticals Inc. | 3 | $28 |
| Dexcom, Inc. | 1 | $19 |
| Ipsen Biopharmaceuticals, Inc | 1 | $19 |
| E.r. Squibb & Sons, L.L.C. | 1 | $18 |
| Calliditas Therapeutics US Inc. | 1 | $18 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $17 |
| Genentech USA, Inc. | 1 | $17 |
| Xeris Pharmaceuticals, Inc. | 1 | $16 |
| GSK | 1 | $15 |
| Pfizer | 1 | $14 |
How this compares
$1,189 in reported general payments places this provider in the 75th percentile of 73 nephrology providers in Iowa.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 121 | $87,873 |
| JanuviaSitagliptin Phosphate | 81 | $58,558 |
| XareltoRivaroxaban | 63 | $48,027 |
| Bydureon BciseExenatide Microspheres | 37 | $31,270 |
| MyrbetriqMirabegron | 40 | $17,437 |
| Spiriva HandihalerTiotropium Bromide | 16 | $16,369 |
| OzempicSemaglutide | 16 | $15,262 |
| MounjaroTirzepatide | 11 | $12,787 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 140 | $10,214 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 311 | $10,209 |
| Tresiba Flextouch U-100Insulin Degludec | 12 | $9,214 |
| Incruse ElliptaUmeclidinium Bromide | 17 | $8,220 |
| SymbicortBudesonide/Formoterol Fumarate | 24 | $8,049 |
| Atorvastatin Calcium | 845 | $7,254 |
| Novolog FlexpenInsulin Aspart | 54 | $7,119 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $14 | $87,873121 claims |
| Johnson & JohnsonXarelto, Procrit | $73 | $54,35894 claims |
| Novo NordiskOzempic, Tresiba, Fiasp, Levemir | $138 | $25,57357 claims |
| AstraZenecaSymbicort, Lokelma | $108 | $14,09736 claims |
| Lilly USA, LLCMounjaro | $70 | $12,78711 claims |
| GSKIncruse Ellipta | $15 | $8,22017 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 73 nephrology providers in Iowa.
Other nephrology in Clinton
- Craig ShadurDes Moines$314K
- Andrew BlandDubuque$76K
- Lawrence HunsickerIowa City$70K
- Ashar LuqmanSioux City$56K
- Jeremy PepinCouncil Bluffs$42K
- Prem ChandranDes Moines$19K
- Lama NoureddineIowa City$7K
- Benjamin GriffinIowa City$6K
- Mony FraerIowa City$5K
- Jerold ErlandsonSioux City$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.